Latest News about SGEN
Recent news which mentions SGEN
From Benzinga
From Motley Fool
2 Growth Stocks That Have Crashed but Are Still Great Long-Term Buys
February 16, 2022
From Motley Fool
Astellas Pharma - Seagen's Enfortumab Shows 36% Pathologic Complete Response In Bladder Cancer Patients
February 15, 2022
From Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
February 11, 2022
From Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
February 11, 2022
From Benzinga
Netflix And Sirius XM Lead The Nasdaq Sharply Lower
February 10, 2022
From Benzinga
Stocks That Hit 52-Week Lows On Thursday
February 10, 2022
From Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
February 10, 2022
From Benzinga
The Daily Biotech Pulse: AstraZeneca Q4 Gets COVID Boost, Seagen Plunges On Earnings, Adcom Test Awaits Lilly
February 10, 2022
From Benzinga
10 Biggest Price Target Changes For Thursday
February 10, 2022
From Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
February 10, 2022
From Benzinga
Why Are Seagen Shares Sinking Today?
February 10, 2022
From Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
February 09, 2022
From Benzinga
The Daily Biotech Pulse: Bristol-Myers Squibb Announces $5B Accelerated Buyback, Qiagen Reaps COVID Testing Windfall, WORLDSymposium Presentations Kick In
February 09, 2022
From Benzinga
Earnings Scheduled For February 9, 2022
February 09, 2022
From Benzinga
A Peek Into The Markets: US Stock Futures Down; Crude Oil Falls Over 1%
February 07, 2022
From Benzinga
The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, IPOs And More
February 06, 2022
From Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 31, 2022
January 31, 2022
From Benzinga
What's Behind Bristol Myers Squibb's Latest Partnership?
January 22, 2022
From Motley Fool
Seagen's SEA-CD40 Combo Regime Shows Preliminary Antitumor Activity In Pancreatic Cancer
January 19, 2022
From Benzinga
Stocks That Hit 52-Week Lows On Tuesday
January 18, 2022
From Benzinga
2 Risky Growth Stocks That Could Make You Filthy Rich
January 16, 2022
From Motley Fool
4 Biotech Acquisitions We'd Like to See in 2022
January 14, 2022
From Motley Fool